Objectives: The aim of this study was to update data on levofloxacin/ciprofloxacin and triple resistance (resistance to metronidazole, clarithromycin and levofloxacin/ciprofloxacin) in Helicobacter pylori clinical isolates and to identify the impact of prior eradication therapies on their development.
Introduction
Nearly a quarter of the German population is colonized with Helicobacter pylori, but only a fifth becomes symptomatic with gastritis and complications such as peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. 1, 2 In previously untreated patients, the German S3-guideline 'Helicobacter pylori and gastroduodenal ulcer disease' and the National Reference Centre for Helicobacter pylori recommend empirical standard first-line therapies consisting of clarithromycin and amoxicillin or metronidazole combined with a proton pump inhibitor (PPI) to eradicate the bacteria. 1 After unsuccessful first-line therapies, second-line treatments including amoxicillin and levofloxacin are widely recommended without prior resistance testing. 1, 3 Levofloxacin is well tolerated and has been shown to be highly effective against H. pylori, but resistance has risen. 4 -6 In several countries dramatically high resistance rates to quinolones have been reported, in particular in Portugal, Hungary, Austria, Belgium, France, Italy and Germany. 4 -7 We tested the antimicrobial susceptibility of 5296 clinical isolates obtained between 2006 and 2011 and gathered data on patients' previous eradication therapies. We show that resistance to levofloxacin/ciprofloxacin is a serious issue in Germany and that the percentage of isolates with combined resistances to metronidazole, clarithromycin and levofloxacin/ciprofloxacin has greatly increased. We challenge the use of levofloxacin without prior susceptibility testing and/or a carefully taken medical history of the patient and recommend antibiogram-adapted second-line therapies or therapy regimens containing antibiotics with low resistance rates.
Materials and methods

Gastric specimens
Between January 2006 and December 2011, a total of 5296 H. pylori strains were isolated from gastric tissue samples sent to our diagnostic laboratory by gastroenterologists from all across Germany. Samples were taken from individuals resident in Baden-Wü rttemberg (n¼1547), North Rhine Westphalia (n ¼1317), Lower Saxony (n ¼733), Bavaria (n ¼532), the new federal states including Berlin (n¼454), RhinelandPalatinate and Saarland (n ¼304), Hesse (n¼249) and Hamburg, Bremen and Schleswig-Holstein (n¼154); the origin of six samples could not be evaluated. Isolates were recovered from patients suffering from gastritis (n¼2850; 53.9%), peptic ulcer disease (n¼460, 8.7%), functional dyspepsia (n¼300; 5.6%), macroscopically regular mucosa (n ¼42; 0.8%) or cancer/MALT lymphoma (n¼16; 0.3%); for 1628 patients (30.7%) information on underlying diseases was not available. Prior H. pylori eradication therapies were reported for 3634 patients (68.6%) with information on the antimicrobials used given for 3128 (59.1%) patients; 4.8% (n¼254) of the patients had never been treated before, and for 26.6% (n¼1408), data on earlier antimicrobial eradication treatments were lacking. Previous treatments included amoxicillin and clarithromycin (n¼1225 of 3128; 39.2%); amoxicillin, clarithromycin and metronidazole (n¼971; 31.1%); metronidazole and clarithromycin (n¼178; 5.7%); amoxicillin, clarithromycin and quinolones (n ¼158; 5.1%); amoxicillin, clarithromycin, metronidazole and quinolones (n¼117; 3.7%); amoxicillin, clarithromycin, metronidazole, rifabutin and quinolones (n ¼46; 1.5%); other quinolone-based therapies (n¼ 122; 3.9%) and others (n ¼311; 9.9%). Data on the exact number of prior eradication therapies were available for 2133 (40%) patients: 38.5% (n ¼821 of 2133) had one; 43.2% had two; 12.6% (n ¼268) had three; 3.6% (n¼77) had four and 2.1% (n¼45) had five or more. For 1501 patients, no exact numbers on prior eradication attempts were available.
Culture and antimicrobial susceptibility testing
All isolates were grown and identified as H. pylori as described earlier. 8 Antimicrobial susceptibility to amoxicillin, metronidazole, clarithromycin, ciprofloxacin (in 2006 and 2007), levofloxacin (from 2008 on), tetracycline and rifampicin was tested by using the Etest method (Alere, Italy) as described earlier, applying the following resistance breakpoints: metronidazole, 8 mg/L; clarithromycin, 1 mg/L, ciprofloxacin/levofloxacin, 1 mg/L; amoxicillin, 1 mg/L; tetracycline, 1 mg/L; and rifampicin, 4 mg/L. 9, 10 Screening for mutations in gyrA Mutations in gyrA conferring resistance to quinolones were identified by either PCR and sequencing or by using the GenoType HelicoDR w (Hain Life Science, Germany) molecular genetic assay as described previously.
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Statistical analysis
For statistical data analysis, SAS 9.3 (SAS, Cary, NC, USA) was used. Hypothesis testing for differences of resistance proportions was done with logistic regression. The log-odds of the binary resistance values were modelled with categorical predictors pre-treatment, year and federal states. P values ≤0.05 were considered significant.
Results
Overall antimicrobial resistance in H. pylori clinical isolates
Of a total of 5296 H. pylori isolates, 67.1% (n¼ 3555) were resistant to metronidazole, 67.1% (n¼ 3553) were resistant to clarithromycin, 33.4% (n ¼1771) were resistant to both metronidazole and clarithromycin, 24.9% (n¼1318) were resistant to levofloxacin/ciprofloxacin and 16.3% (n¼ 861) were triple resistant to metronidazole, clarithromycin and levofloxacin/ciprofloxacin; resistances to tetracycline and rifampicin/rifabutin were rare and resistance to amoxicillin was not detected.
Antimicrobial resistance was dependent on prior eradication therapies, as pre-treated patients (n¼ 3634) showed significantly higher resistance than untreated patients (n¼ 254) to metronidazole (69.7% versus 36.2%, P,0.0001), clarithromycin (73.7% versus 20.9%, P,0.0001) and levofloxacin/ciprofloxacin (26.7% versus 10.6%, P,0.0001). Double resistances to metronidazole and clarithromycin (36.8% versus 10.2%, P,0.0001) and triple resistances (18.1% versus 1.6%, P,0.0001) were significantly more common in pre-treated patients compared with untreated ones ( Figure S1 , available as Supplementary data at JAC Online).
Resistances in the various German federal states grossly were evenly distributed. Exceptions were double resistances to metronidazole and clarithromycin, which were considerably lower in Baden-Wü rttemberg (24.0%), and levofloxacin/ciprofloxacin (33.7%) and triple (24.9%) resistances, which were strikingly higher in Hesse ( Figure S2 , available as Supplementary data at JAC Online).
Trend of overall levofloxacin/ciprofloxacin resistance and triple resistance to metronidazole, clarithromycin and levofloxacin/ciprofloxacin Levofloxacin/ciprofloxacin resistance has significantly (P,0.0001) increased from 20.9% in 2006 to 29.1% in 2011, and triple resistance has significantly (P ¼0.003) increased from 12.9% in 2006 to 18.6% in 2011. Overall resistance to levofloxacin/ciprofloxacin and triple resistance was significantly higher in pre-treated patients when compared with previously untreated patients (P,0.0001). In 2011, levofloxacin/ciprofloxacin and triple resistance reached dramatic levels of 30.6% and 19.7% in pre-treated patients, whereas isolates from previously untreated individuals showed far lower resistance rates of 18.8% and 4.2%, respectively (Figure 1 ).
Prior quinolone-based eradication attempts were associated with greater resistance to levofloxacin/ciprofloxacin and triple resistances: 443 of 3128 patients were previously treated with an eradication regimen including quinolones, while 2685 were administered other antimicrobials. In contrast to metronidazole (70.9% versus 70.5%, P ¼ 0.87) and clarithromycin (71.3% versus 75.5%, P ¼ 0.064) resistance, which were only slightly different, quinolone-pre-treated patients harboured significantly fewer clarithromycin and metronidazole double-resistant strains (25.3% versus 39.4%, P,0.0001), but significantly more levofloxacin/ ciprofloxacin-resistant (44.5% versus 24.2%, P,0.0001) and triple-resistant (28.7% versus 16.9%, P, 0.0001) strains (Figure 2 ). The majority of these patients had undergone prior eradication therapies on multiple occasions.
Mutations associated with levofloxacin/ciprofloxacin resistance
We analysed a random selection of 85 levofloxacin-resistant strains with MICs ranging from 1.5 to 32 mg/L for the presence High quinolone resistance in German H. pylori isolates of resistance-associated mutations in the gyrA gene. In 30 isolates we identified mutations resulting in an amino acid replacement of asparagine with lysine at position 87 (N87K). Fifty-five strains revealed mutations at amino acid 91; 26 isolates had an amino acid exchange from aspartate to asparagine (D91N), 20 isolates from aspartate to tyrosine (D91Y) and 9 from aspartate to glycine (D91G). All 43 levofloxacin-susceptible isolates tested with MICs ,0.75 mg/L showed wild-type gyrA sequences. No correlation between the kind of mutation and the resulting MIC of levofloxacin was observed.
Discussion
Prior unsuccessful clarithromycin-and/or metronidazole-based eradication therapies of H. pylori result in resistance to these key antibiotics and require other antimicrobials such as levofloxacin. 1, 3 The percentage of levofloxacin/ciprofloxacin-and triple-resistant H. pylori isolates, however, steadily increased up to 29.1% and 18.6%, respectively, in 2011.
We identified unsuccessful and, in particular, quinolone-based eradications as a major risk factor for the development of levofloxacin/ciprofloxacin and triple resistance. Even though significantly lower, quinolone resistance in patients who had never undergone H. pylori eradication peaked in 2011 with 18.8%, which may reflect the widespread use of quinolones in empirical treatments of various other bacterial infections.
In view of the high percentage of quinolone-resistant strains, we strongly advise against the use of levofloxacin in empirical second-line eradication therapies and encourage gastroenterologists to have resistance to levofloxacin tested ahead of the planned administration. Prior susceptibility testing does not guarantee successful therapy outcomes, but it allows for individually tailored therapies without the useless administration of inefficient antimicrobials and their associated adverse effects. Furthermore, it may reduce costs and may prevent the development of resistance to reserve antimicrobials.
If antimicrobial susceptibility testing is not available, e.g. due to a lack of infrastructure, genotypic resistance testing is a useful and reliable alternative. 12 -15 It is quick, robust, works with gastric tissue samples and predicts phenotypic resistance with high specificity and sensitivity. If neither is possible, gastroenterologists may prefer quadruple therapies including metronidazole, tetracycline, bismuth salt and PPI, which have been shown to be effective and bypass putative quinolone resistance. 16, 17 In summary, we have shown that resistance to levofloxacin/ ciprofloxacin and triple resistance to metronidazole, clarithromycin and levofloxacin/ciprofloxacin by now has reached worrying levels. If susceptibility testing is not available, quinolones should be used with care in H. pylori eradication and only after taking a thorough antibiotic history of the patient.
Studies and programmes to keep the development of antimicrobial resistance in H. pylori under surveillance are required. The continuous documentation of resistance development may enable us to identify further risk factors for the development of resistance and to derive evidence-based therapeutic recommendations for empirical first-line and second-line treatment regimens.
